Assessment of the course of AαVal541 in plasma over 4 weeks after a single intravenous dose of 240 mg/kg AAT in treatment-naive proteinase-3-generated AaVal541 in deficient patients with genotype Null/Null and Z/Null
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Therapeutic Use
Most Recent Events
- 09 Feb 2022 New trial record